Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY presentation @ August 12th Cannacord fireside chat

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Aug 13, 2021 3:20pm

145 Views

Post# 33702022

RE:ONCY presentation @ August 12th Cannacord fireside chat

replying to note, unnote and Canada fan,

I agree it will be some years before they could market their BC treatment, unless they get breakthrough status and fast FDA and EMA approval, which is certainly within the realm of possibility. I thought ithat should happen years ago.

Remember, folks, ONCY poses no adverse health effects beyond its warming up of your immune system with a mild flu. What other cancer treatment of any kind, other than voodoo type treatments, can say that?

I think Canadafan and has explained our situation clearly.

<< Previous

Bullboard Posts

Next >>

Barrick Gold employees detained in Mali amid ongoing dispute